Solabegron
- Generic Name
- Solabegron
- Drug Type
- Small Molecule
- Chemical Formula
- C23H23ClN2O3
- CAS Number
- 252920-94-8
- Unique Ingredient Identifier
- 55P6YH9O6N
- Background
Solabegron (GW-427,353) is a selective ฮฒ3 adrenoceptor agonist being developed for the treatment of overactive bladder and irritable bowel syndrome.
- Indication
Investigated for use/treatment in diabetes mellitus type 2, irritable bowel syndrome (IBS), and urinary incontinence.
A Study Evaluating the Potential of BMS-984923 to Alter the Systemic Exposure of Three Orally Administered Probe Substrates
- Conditions
- Drug Drug Interaction (DDI)
- Interventions
- First Posted Date
- 2024-10-09
- Last Posted Date
- 2025-02-07
- Lead Sponsor
- Allyx Therapeutics
- Target Recruit Count
- 36
- Registration Number
- NCT06632990
- Locations
- ๐บ๐ธ
Spaulding Clinical Research, West Bend, Wisconsin, United States
A Study to Assess the Safety of BMS-984923 Compared to Placebo, in People With Parkinson's
- First Posted Date
- 2024-03-13
- Last Posted Date
- 2024-03-18
- Lead Sponsor
- Allyx Therapeutics
- Target Recruit Count
- 18
- Registration Number
- NCT06309147
- Locations
- ๐บ๐ธ
Duke Clinical Research Institute, Durham, North Carolina, United States
Food Effect Study of BMS-984923 in Healthy Older Adult Volunteers
- First Posted Date
- 2023-04-18
- Last Posted Date
- 2024-07-30
- Lead Sponsor
- Allyx Therapeutics
- Target Recruit Count
- 12
- Registration Number
- NCT05817643
- Locations
- ๐บ๐ธ
Spaulding Clinical Research, West Bend, Wisconsin, United States
A Multiple Ascending Dose Study in Healthy Volunteers and Patients With Alzheimer's Disease
- First Posted Date
- 2023-04-07
- Last Posted Date
- 2024-07-30
- Lead Sponsor
- Allyx Therapeutics
- Target Recruit Count
- 50
- Registration Number
- NCT05804383
- Locations
- ๐บ๐ธ
Spaulding Clinical Research, West Bend, Wisconsin, United States
๐บ๐ธYale University, New Haven, Connecticut, United States
Evaluating the Safety, Tolerability, Pharmacokinetics and Receptor Occupancy of BMS-984923
- First Posted Date
- 2021-03-18
- Last Posted Date
- 2024-08-27
- Lead Sponsor
- Yale University
- Target Recruit Count
- 36
- Registration Number
- NCT04805983
- Locations
- ๐บ๐ธ
Yale University, New Haven, Connecticut, United States
A Study to Evaluate Once Daily Low Dose and High Dose Solabegron or Placebo Given for 12 Weeks to Treat Women With Symptoms of Overactive Bladder: Sudden Urge to Urinate, Frequent Urination Associated With Wetting Episodes (VEL-2001)
- Conditions
- Overactive Bladder
- Interventions
- First Posted Date
- 2018-07-20
- Last Posted Date
- 2020-03-02
- Lead Sponsor
- Velicept Therapeutics, Inc.
- Target Recruit Count
- 1413
- Registration Number
- NCT03594058
- Locations
- ๐บ๐ธ
Velicept Investigative Site - Doral(2), Doral, Florida, United States
๐บ๐ธVelicept Investigative Site - Hialeah, Hialeah, Florida, United States
๐บ๐ธVelicept Investigative Site - Tucson, Tucson, Arizona, United States
Evaluation of the Efficacy and Safety of Solabegron Tablets for Treatment of Overactive Bladder in Adult Women
- Conditions
- Overactive Bladder
- Interventions
- First Posted Date
- 2018-03-23
- Last Posted Date
- 2020-03-02
- Lead Sponsor
- Velicept Therapeutics, Inc.
- Target Recruit Count
- 438
- Registration Number
- NCT03475706
- Locations
- ๐บ๐ธ
Velicept Investigative Site - Kalamazoo, Kalamazoo, Michigan, United States
๐บ๐ธVelicept Investigative Site - Los Angeles, Los Angeles, California, United States
๐บ๐ธVelicept Investigative Site - Boston, Boston, Massachusetts, United States
Evaluate the Safety, Tolerability and PK of Different Formulations of Orally Administered Solabegron in Healthy Male Subjects
- Conditions
- Healthy Subjects, Overactive Bladder
- Interventions
- First Posted Date
- 2016-10-19
- Last Posted Date
- 2019-04-24
- Lead Sponsor
- Velicept Therapeutics, Inc.
- Target Recruit Count
- 24
- Registration Number
- NCT02938507
A Study To Test The Interaction of Two Medications for Treatment of Overactive Bladder
- Conditions
- Overactive Bladder
- First Posted Date
- 2007-07-16
- Last Posted Date
- 2015-04-15
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 24
- Registration Number
- NCT00501267
- Locations
- ๐บ๐ธ
GSK Investigational Site, Tacoma, Washington, United States
A Two-Part Study to Determine: Best Medication Formulation and Food Effect
- Conditions
- Overactive Bladder
- First Posted Date
- 2007-01-29
- Last Posted Date
- 2008-10-07
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 18
- Registration Number
- NCT00427596
- Locations
- ๐บ๐ธ
GSK Investigational Site, Buffalo, New York, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.